Key Points
- Insider sale: John Rondoni sold 109 shares on Jan. 9 at an average price of $100, reducing his ownership by 0.78% to 13,797 shares valued at about $1.38 million, as disclosed in an SEC filing.
- Strong recent results: Inspire beat expectations on Nov. 3 with $0.38 EPS vs. a ($0.15) consensus and $224.5M revenue (up 10.5% YoY), and analysts hold an average rating of "Moderate Buy" with a $136.35 target.
- Stock profile: Shares opened around $96.99 (1‑year range $70.77–$203.12), market cap roughly $2.82B, PE ~65.98, and institutional investors own about 94.91% of the company.
Inspire Medical Systems, Inc. (NYSE:INSP - Get Free Report) insider John Rondoni sold 109 shares of the firm's stock in a transaction dated Friday, January 9th. The shares were sold at an average price of $100.00, for a total value of $10,900.00. Following the transaction, the insider directly owned 13,797 shares in the company, valued at $1,379,700. This trade represents a 0.78% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.
Inspire Medical Systems Trading Down 1.4%
NYSE INSP opened at $96.99 on Tuesday. The firm has a market cap of $2.82 billion, a PE ratio of 65.98, a price-to-earnings-growth ratio of 9.97 and a beta of 0.72. Inspire Medical Systems, Inc. has a 1-year low of $70.77 and a 1-year high of $203.12. The stock has a 50-day moving average of $105.22 and a 200-day moving average of $99.14.
Inspire Medical Systems (NYSE:INSP - Get Free Report) last announced its quarterly earnings results on Monday, November 3rd. The company reported $0.38 EPS for the quarter, topping analysts' consensus estimates of ($0.15) by $0.53. The business had revenue of $224.50 million for the quarter, compared to analysts' expectations of $220.39 million. Inspire Medical Systems had a return on equity of 9.41% and a net margin of 5.05%.The business's quarterly revenue was up 10.5% on a year-over-year basis. During the same period in the previous year, the firm earned $0.60 EPS. As a group, equities research analysts forecast that Inspire Medical Systems, Inc. will post 2.16 earnings per share for the current fiscal year.
Analyst Ratings Changes
A number of research analysts have issued reports on the stock. KeyCorp reissued a "sector weight" rating on shares of Inspire Medical Systems in a research report on Tuesday, November 4th. Evercore ISI decreased their price target on shares of Inspire Medical Systems from $150.00 to $125.00 and set an "outperform" rating for the company in a research note on Tuesday, October 7th. Stifel Nicolaus set a $110.00 price objective on Inspire Medical Systems and gave the company a "buy" rating in a research report on Monday, November 24th. Oppenheimer reissued an "outperform" rating on shares of Inspire Medical Systems in a research report on Friday, December 19th. Finally, Truist Financial lowered their target price on Inspire Medical Systems from $165.00 to $120.00 and set a "buy" rating for the company in a research note on Thursday. Eleven investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $136.35.
Get Our Latest Research Report on INSP
Institutional Investors Weigh In On Inspire Medical Systems
A number of institutional investors have recently made changes to their positions in INSP. Royal Bank of Canada increased its position in shares of Inspire Medical Systems by 16.0% during the first quarter. Royal Bank of Canada now owns 32,769 shares of the company's stock valued at $5,220,000 after acquiring an additional 4,528 shares in the last quarter. Integrated Wealth Concepts LLC purchased a new stake in Inspire Medical Systems during the 1st quarter valued at $524,000. Goldman Sachs Group Inc. increased its holdings in shares of Inspire Medical Systems by 57.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 51,422 shares of the company's stock worth $8,190,000 after purchasing an additional 18,857 shares in the last quarter. Voya Investment Management LLC raised its stake in shares of Inspire Medical Systems by 5.3% in the first quarter. Voya Investment Management LLC now owns 164,936 shares of the company's stock worth $26,271,000 after purchasing an additional 8,361 shares during the last quarter. Finally, Fox Hill Wealth Management lifted its holdings in shares of Inspire Medical Systems by 23.8% during the second quarter. Fox Hill Wealth Management now owns 5,845 shares of the company's stock valued at $758,000 after purchasing an additional 1,122 shares in the last quarter. Hedge funds and other institutional investors own 94.91% of the company's stock.
About Inspire Medical Systems
(
Get Free Report)
Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company's flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.
The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
